Status:
COMPLETED
Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma
Lead Sponsor:
Ohio State University Comprehensive Cancer Center
Conditions:
Central Nervous System Lymphoma
Diffuse Large B-Cell Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
This study evaluates pharmacogenomic effects on high-dose methotrexate clearance in patients with diffuse large B-cell lymphoma.
Detailed Description
PRIMARY OBJECTIVES: I. To identify SNPs associated with delayed MTX clearance. II. To explore any association between SNPs and increased toxicity. OUTLINE: This is an observational study. Participa...
Eligibility Criteria
Inclusion
- \* Adult (age ≥ 18 years at diagnosis)
- Diagnosis of DLBCL or PCNSL
- Planned to undergo treatment with HDMTX (≥ 3 g/m\^2) at the James Cancer Hospital.
- Note: patients with CKD are eligible to participate regardless of eGFR provided the treating physician is planning a dose of HDMTX of at least 3 g/ m\^2.
- Ability to provide informed consent.
Exclusion
- \* Patients with a "currently active" second malignancy that, in the opinion of the principal investigator, will interfere with patient participation, or confound data interpretation
- Pregnancy (positive serum or urine pregnancy test), lactating or breast feeding
- Prisoners or incarcerated patients
- Total bilirubin \> 5 mg/dL
Key Trial Info
Start Date :
May 10 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 23 2025
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06031194
Start Date
May 10 2023
End Date
December 23 2025
Last Update
January 6 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States, 43210